Healing chronic wounds
Factor Therapeutics is developing VF-001, an advanced wound care product that promotes healing in chronic wounds. It is about to commence a randomised Phase IIb trial targeting venous leg ulcers, with top-line results anticipated in Q417. There is an urgent need for better therapies for this condition, with 40-70% of ulcers remaining unhealed after six months of the best current treatments. We value Factor at A$102m or A$0.14/share.Factor Therapeutics is engaged in the development and commercialization of its proprietary intellectual property in wound care. Co.'s lead program, VF-0013 is a biologic product for wound care that harnesses a targeted growth factor approach to accelerate the healing process. This is a platform technology with multiple clinical applications and is being developed to treat chronic wounds that can persist for months or even years. Co. has undertaken a U.S.-centric development program, and is on the cusp of initiating a Phase II trial of its lead program in the U.S., subject to FDA approval. This Phase II program is designed to deliver the initial treatment indication of venous leg ulcers.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.